Healthcare Industry News:  Parkinson's disease 

Regenerative Medicine Neurology

 News Release - February 27, 2006

Stem Cell Therapy International Reports Successful Treatment of Multiple Sclerosis Patient With Stem Cell Transplantation Therapy

Patient Describes 'Dramatic' Improvement in Video Clip Posted on Company Web Site

TAMPA, FL--(Healthcare Sales & Marketing Network)--Feb 27, 2006 -- Stem Cell Therapy International, Inc. (Other OTC:SCII.PK ), a leading company in the field of research and development of stem cell transplantation (SCT) therapy and regenerative medicine, reported today the successful results of a case of stem cell transplantation performed last November on a 42-year-old man, who was diagnosed with progressive multiple sclerosis (MS) three years ago.

Samuel Bonnar, a shop owner in Newtownabbey, Ireland, was experiencing increasing debilitation including difficulty speaking and the effects of poor circulation. He needed crutches to walk and was able to climb stairs only by lifting his left leg with his arm with each step. He had received traditional treatment for MS at two hospitals in Ireland with little to no effect. The traditional prognosis for MS victims is ever-increasing debilitation leading to death.

Calvin Cao, CEO of Stem Cell Therapy International (SCTI), said Mr. Bonnar sought alternative treatment for his condition, first learning about stem cell transplantation therapy in the United Kingdom from the non-profit newsletter, "Different Strokes," that detailed the positive treatment of Belfast native Ian McBride, who had suffered a stroke and was successfully treated with stem cell transplantation at the SCTI affiliated medical facility in 2005.

Calvin Cao said SCTI arranged for Mr. Bonnar to be treated with injections of a stem cell biological solution at the SCTI affiliate medical facility in Kiev, Ukraine on November 27th, 2005. "The positive results of the therapy were remarkable and almost instant," Mr. Cao reported. "Within a few days, Mr. Bonnar's speech and mobility were vastly improved and after two weeks he had regained the ability to climb a full set of stairs without having to lift his left leg with his hand. Numbness in the fingertips of both hands subsided and occurs now only occasionally."

In a correspondence with SCTI in mid-December, Mr. Bonnar recounted the results: "After the treatment, my speech improved dramatically. It is almost back to the way it was. Other people have commented on the dramatic difference. The doctors at the hospital said it would take two-to-three months to see the full effect of the stem cell transplantation therapy. It has now been 2 1/2 weeks since the treatment and already there is noticeable improvement."

SCTI has posted a video clip on its web site made in Kiev that shows Sam Bonnar describing his condition both before and after the treatment. To view the video clip, go to:

Calvin Cao said Mr. Bonar's progress will be monitored over the next six months. There is no follow-up treatment planned at this time. He said that Dr. Weinwen Deng, Ph.D., an expert in stem cell therapy from Tulane University and a member of the SCTI Medical and Scientific Advisory Board, has been asked to prepare a scientific abstract on the case and submit it to an appropriate scientific journal for publication.

"Sam Bonnar's improvement, along with Ian McBride's, provides increasing evidence of the efficacy of stem cell transplantation therapy and, we believe, will encourage stem cell researchers worldwide to promote widespread acceptance of stem cell therapy worldwide," Mr. Cao said.

He said, "The stem cell therapy procedure Mr. Bonnar received at the clinic is based on the use of the stem cell biological solution, which is part of the exclusive license agreement SCTI has for the use of 26 patents related to stem cell technology from the Institute of Cell Therapy (ICT). Mr. Bonnar's is another successful case we have treated using our stem cell biological solution and the results have exceeded our expectations."

With the enactment of Proposition 71 in California in November 2004, a fund of $3 Billion was created to fund stem cell research. Since then four other states, New Jersey, Connecticut, Illinois and Wisconsin, have allocated funds for stem cell research. For additional information about SCTI and its stem cell treatment procedures, you can visit their website @

About Stem Cell Therapy International

Stem Cell Therapy International, Inc. is engaged in the field of research and development of regenerative medicine. SCTI manufactures allo stem cell biological solutions that are currently being used in the treatment of patients suffering from degenerative disorders of the human body such as Alzheimer's, Parkinson's disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer. The Company has established agreements with highly specialized, professional medical treatment facilities around the world in locations where stem cell transplantation therapy is approved by the appropriate local government agencies. SCTI intends to provide these biological solutions containing stem cell products in the United States to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials. Its products, which are available now, include various allo stem cell biological solutions containing (human stem cells), low-molecular proteins and human growth factor hormones.

Forward-Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.

Source: Stem Cell Therapy International

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.